AstraZeneca has decided not to file regulatory submissions for Recentin (cediranib) to treat first-line metastatic colorectal cancer.

The decision followed the results of a Phase III study where the drug met the co-primary end point to improve progression-free survival but failed to improve overall survival.

The study, which tested cediranib plus chemotherapy against bevacizumab plus chemotherapy, did not meet the primary endpoint.

AstraZeneca is still, however, expecting results of a Phase III study evaluating cediranib to treat recurrent glioblastoma and will examine if the drug could treat other tumours.